RE:Ceapro / Aeterna Merger Assurances"Interestingly, I spoke to Gilles several times over the last many years about Aeterna Zentaris. I told Gilles many times that I though Zentaris was a worthless pieces of junk that had cash, that was it. Gilles Gagnon agreed with that. The only positive thing he had to say was that there were some strategic people in Germany that were very proficient and would hire them if he could." AEZS got full control of its diagnostic test back from Novo Nordisk in May 2023. That's just seven months before the annuncement of the merger. The pediatric trial had been very slow. With the last patient last visit completed in June the burn rate for the pediatric trial is now over. With full control of the asset and the burn rate from the pediatric trial behind it the value can change. The diagnostic is now a potential cash infusion and cashcow with a new licensing deal and July 2023 AEZS stated that based on outreach it expected a new North American deal. They are also looking at licensing to other global juristictions. Places like China largely only test for pediatric growth hormone deficiency. As a Director of AEZS Gilles was well positioned to guage the interest in a new licensing deal(s). Top-line results are due in the next 40 days for the pediatric trial. We will find out soon enough what the diagnostic is worth. There are no guarentees with clinical trials. The amount paid previously for a North American deal was considerable; but things can change.
AEZS also has considerable tax loss carryforwards and other portfolio assets that may have now reached an inflection point. The preclinical cash burn may be behind and a preclinical proof established. Meetings with regulators were planned to establish the path forward. There has also been talk of potential partnering. Moving an asset into human testing and having a defined regulatory path forward including with a potential partner can add considerable value. The markets AEZS's products target are in the potential billions. With a potential interest rate cutting cycle just starting and that favorable for biotech acquiring the assets could be good timing.
You say Gilles was hot on "strategic people" in AEZS who were "very proficient" and he would hire them. Now Gilles has them and I wonder why they were so special to Gilles. Maybe we will find out with the "fulsome" update expected "shortly" why he liked the strategic people. The strategic acquistion is now complete and Ronnie Miller says they are now optimised to bring transformational products to market. Can the strategic people add to the value of PGX? Given they know Gilles have any synergies been investigated with PGX? AEZS has a portflio of science that it has investigated over a long period of time and PGX is a delivery technology. Maybe there is nothing but it is interesting that AEZS's diagnostic asset... They are currenly investigating a new formulation for ALS. Ghrelin has numerous potential therapeutic benefits making targeted delivery important to limit the side-effects of delivering the drug.
Perplexity Ai has some comments but with Ai it can be a hallucination.
-----
Ceapro's inhaled yeast beta glucan, specifically PGX-processed yeast beta glucan (PGX-YBG), shows promise as a therapeutic agent for targeting the lungs and modulating macrophages, which could potentially complement the effects of ghrelin in treating conditions like ALS and lung diseases. Potential Benefits of PGX-Processed Yeast Beta Glucan
- Macrophage Modulation: PGX-YBG has demonstrated the ability to reprogram macrophages in the lungs. This is significant because macrophages play a crucial role in immune response and fibrosis, which are relevant in both lung conditions and neurodegenerative diseases like ALS.
- Inhalable Formulation: The PGX technology allows yeast beta glucan to be processed into microparticles that are small enough for effective inhalation. This means it can be delivered directly to the lungs, which is beneficial for treating lung diseases and potentially for systemic effects through the respiratory system.
- Immunomodulatory Properties: PGX-YBG has shown significant immunomodulatory effects, which could help in managing inflammation—a common factor in both ALS and lung diseases. This property might enhance the therapeutic effects when used alongside ghrelin, which also has anti-inflammatory and neuroprotective roles.
Combining with Ghrelin
While ghrelin is being explored for its neuroprotective and metabolic benefits in ALS, combining it with PGX-YBG could potentially offer a multifaceted approach by targeting both the nervous system and the immune system. Ghrelin could address systemic metabolic and neurodegenerative aspects, while PGX-YBG could provide localized treatment in the lungs and modulate immune responses through macrophage reprogramming. However, further research and clinical trials would be necessary to evaluate the safety, efficacy, and potential synergistic effects of this combination therapy.